Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Contractor Coding Difficulties Argue For Increased HCFA Funding - MGMA

This article was originally published in The Gray Sheet

Executive Summary

Medicare intermediary contractors likely will have difficulty processing the new codes for colonoscopy procedures when coverage rules change July 1, Jyl Bradley, representing the Medical Group Management Association, testified April 4 at a joint hearing of the House Energy & Commerce/Health and Oversight Subcommittees.

You may also be interested in...



House Oversight Panel Considers HCFA Reforms, Expedited Review Process

The Health Care Financing Administration should develop an expedited review track for breakthrough technologies such as intracoronary radiation therapy, Jeffrey Popma, MD, Brigham and Women's Hospital, Boston, recommended March 1 at a House Energy and Commerce/Health and Oversight & Investigations joint subcommittee hearing.

Medicare Giveback Package Includes $1.5 Bil. For Screening Initiatives

Increasing Medicare payments for bilateral diagnostic mammography using new technologies to 150% of the current physician fee is scored as costing $400 mil. over five years.

California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits

The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT014712

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel